T-cell activator offers protection against coronaviruses in immunocompromised cancer patients

Good news for patients with acquired or congenital immunodeficiency: The results of a clinical phase II study at the University Hospital Tübingen led by Prof. Dr. Juliane Walz and Prof. Dr. Helmut Salih show an effective activation of T cells against the coronavirus. After showing positive results in healthy volunteers in the previous phase I, the T-cell activator CoVac-1 reproduced these effects in cancer patients for the first time. The results have been published in the journal Nature Communications.